我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

慢性充血性心力衰竭患者血浆BCAAs水平的临床研究

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第2期
页码:
152-154
栏目:
临床研究
出版日期:
2014-10-25

文章信息/Info

Title:
Clinical research of plasma BCAAs level in patients with chronic congestive heart failure
作者:
赵晓丽1; 2; 朱 迪1; 张静隆1; 廉 坤1; 刘 毅1; 虞成凯3; 陶 凌1
(第四军医大学: 1.西京医院心血管内科，3.军事预防医学院卫生统计学教研室，陕西 西安 710032；
2.扶风县人民医院心血管内科，陕西 扶风 722200)
Author(s):
ZHAO Xiao-li1; 2;  ZHU Di1;  ZHANG Jing-long1;  LIAN Kun1;  LIU Yi1;  YU Cheng-kai3;  TAO Ling1
(1.Department of Cardiology, Xijing Hospital, 3.Department of Health Statistics, Fourth Military Medical University, Shaanxi, Xi’an 710032, China；
2.Department of Cardiology, People’s Hospital of Fufeng County, Fufeng 722200, Shaanxi, China)
关键词:
心力衰竭; 充血性; 慢性; 支链氨基酸; 氨基末端脑钠尿肽前体; 左室射血分数
Keywords:
chronic congestive heart failure;  branched-chain amino acids;  NT-pro-brain natriuretic peptide;  left ventricular ejection fraction
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨研究慢性充血性心力衰竭（CHF）患者血浆支链氨基酸（BCAAs）水平的变化，及其与氨基末端脑钠尿肽前体（NT-pro-BNP）和左室射血分数（LVEF）的相关性。方法:共纳入168例诊断为CHF患者作为病例组，同时随机选择同期体检的41例健康成年人作为对照组。采用ELISA方法测定空腹血浆BCAAs水平、NT-pro-BNP，超声心动图检测LVEF值。比较两组血浆BCAAs水平及其与NT-pro-BNP、LVEF的关系。结果:两组受试者基线资料无明显差异；CHF患者血浆BCAA水平、LVEF均低于对照组，血浆NT-pro-BNP高于对照组(P<0.01)；随着NYHA分级增加，NT-pro-BNP逐渐升高，LVEF逐渐降低(P<0.01)，而BCAAs水平无明显变化；Spearson偏相关分析显示经性别、年龄、收缩压、舒张压、体质量指数校正后，CHF组BCAAs水平与NT-pro-BNP呈负相关(r=-0.168，P<0.05)，而与LVEF无关(r=0.069,P>0.05)。结论:CHF患者血浆BCAAs水平明显低于正常对照组，与NT-pro-BNP水平呈负相关。
Abstract:
AIM:To explore the change of plasma branched-chain amino acids (BCAAs) level in patients with chronic congestive heart failure (CHF) and its correlation with NT-pro-brain natriuretic peptide (NT-pro-BNP) and left ventricular ejection fraction (LVEF). METHODS: Plasma BCAAs and NT-pro-BNP were detected with commercial ELISA kits and LVEF was measured by echocardiography in 168 CHF patients (CHF group) and 41 normal subjects (control group). RESULTS: No significant difference was observed in the general data between groups. The levels of plasma BCAAs and LVEF in CHF group were lower than those in control group, but the level of NT-pro-BNP in the CHF group was higher (all P<0.01). With the increase of NYHA classification, NT-pro-BNP increased (all P<0.01), but plasma BCAAs level did not change significantly (P>0.05). In partial correlation analyses adjusted for gender, age, systolic blood pressure, diastolic blood pressure and body mass index, plasma BCAAs level was negatively correlated with NT-pro-BNP and was not associated with LVEF. CONCLUSION: Plasma BCAA level in CHF group is lower than in control group and is negatively correlated with NT-pro-BNP concentration, indicating that BCAAs might play a role in metabolic remodeling of the failing heart, which provides a novel strategy for treatment of heart failure.

参考文献/References

[1]Springer J,Anker SD,Doehner W.Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure[J].Circ Heart Fail,2010,3(2):181-182.
[2]Ingwall JS.Energy metabolism in heart failure and remodelling[J].Cardiovasc Res,2009,81(3):412-419.
[3]Huang Y,Zhou M,Sun H,et al.Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit?[J].Cardiovasc Res,2011,90(2):220-223.
[4]Shah SH,Crosslin DR,Haynes CS,et al.Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss[J].Diabetologia,2012,55(2):321-330.
[5]Tang WH,Girod JP,Lee MJ,et al.Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure[J].Circulation,2003,108(24):2964-2966.
[6]李旭霞,张 宏,张 宁.超声心动图观察射血分数与心源性猝死的相关性[J].中国医学影像学杂志,2011,19(3):190-192.
[7]Szabó T,Scherbakov N,Sandek A,et al.Plasma adiponectin in heart failure with and without cachexia:catabolic signal linking catabolism, symptomatic status, and prognosis[J].Nutr Metab Cardiovasc Dis,2014,24(1):50-56.
[8]van Bilsen M,van Nieuwenhoven FA.Van der vusse GJ.Metabolic remodelling of the failing heart:beneficial or detrimental?[J].Cardiovasc Res,2009,81(3):420-428.
[9]Revenco D,Morgan JP.Metabolic modulation and cellular therapy of cardiac dysfunction and failure[J].J Cell Mol Med,2009,13(5):811-825.
[10]D'antona G,Ragni M,Cardile A,et al.Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice[J].Cell Metab,2010,12(4):362-372.

备注/Memo

备注/Memo:
收稿日期：2014-07-29.
通讯作者：陶凌，主任医师，主要从事冠心病的基础和临床研究 Email：lingtao2006@gmail.com
作者简介：赵晓丽，主治医师，硕士 Email：zhaoxiaoli05@163.com
更新日期/Last Update: 2014-11-18